Main Article Content

Ellin Rachmawati
Indah Laily Hilmi
Triana Maudy Yulianti Surasa
Dytha Andri Deswati

Page: 1608-1618

Abstract

Health insurance systems face growing challenges in determining which interventions should be financed under limited resources, making it necessary to adopt approaches that can assess both health benefits and economic consequences simultaneously. One widely used approach is cost-utility analysis, which relates intervention costs to utility-based outcomes, particularly quality-adjusted life years (QALYs). This review article aimed to examine the role of cost-utility analysis in supporting decision-making within health insurance systems. This study was conducted as a review article through a systematic literature search in the PubMed database using the keyword “cost-utility analysis” AND “decision making”. The article selection process followed the PRISMA framework. Of the 131 records initially identified, 10 articles met the inclusion criteria after screening titles/abstracts (n=116 excluded) and full-text review (n=5 excluded), and were analyzed using a descriptive narrative approach. The review found that cost-utility analysis has been applied to assess various interventions, including palliative care services, antiviral therapies, artificial intelligence-based screening technologies, chronic disease medications, and national immunization programs. Several interventions were found to be cost-effective or even cost-saving, suggesting their potential to support benefit package expansion and improve the efficiency of health financing. However, other interventions were not considered economically feasible due to high prices, substantial budget impact, and limited reimbursement mechanisms. All reviewed studies originated from Thailand, Tiongkok, Vietnam, Colombia, Jepang, Korea Selatan, dan, Taiwan, Province of China; therefore, direct generalization to the Indonesian context requires further adaptation assessment. These findings indicate that cost-utility analysis plays an important role in informing benefit package design, health technology adoption, price negotiation, and more efficient resource allocation in health insurance systems. Therefore, the integration of cost-utility evidence into health financing policy should be strengthened to ensure that health insurance systems operate in a more rational, efficient, and sustainable manner.

Downloads

Download data is not yet available.

Article Details

How to Cite
Rachmawati, E., Hilmi, I. L., Surasa, T. M. Y., & Deswati, D. A. (2026). Cost-Utility Analysis in Supporting Decision-Making in Health Insurance Systems. Journal of Pharmaceutical and Sciences, 9(2), 1608–1618. https://doi.org/10.36490/journal-jps.com.v9i2.1555
Section
Review Article

References

I. Green Nego et al., “Basic Concepts of Health Economics and their Application in the Health Service System: A Literature Review,” Journal Health & Science : Gorontalo Journal Health and Science Community, 2025, [Online]. Available: https://ejurnal.ung.ac.id/index.php/gojhes/index

D. Despitasari, D. S. Andria, R. Valenti, B. Hartono, and A. G. Daud, “Evaluasi Ekonomi Intervensi Kebijakan Kesehatan untuk Memerangi Penyakit Tidak Menular (PTM): Tinjauan Sistematis: Efektivitas Biaya pada Populasi Berisiko Tinggi,” RIGGS: Journal of Artificial Intelligence and Digital Business, vol. 4, no. 4, pp. 8777–8785, Jan. 2026, doi: 10.31004/riggs.v4i4.5010.

M. Prajuita, I. Filyani, S. Marika, B. Hartono, and A. G. Daud, “Analisis Biaya-Manfaat Telemedicine untuk Tatalaksana Penyakit Kronis: Studi Cost-Benefit pada Pasien Diabetes Melitus Tipe 2,” RIGGS: Journal of Artificial Intelligence and Digital Business, vol. 4, no. 4, pp. 9238–9245, Jan. 2026, doi: 10.31004/riggs.v4i4.5178.

S. Botwright, E. M. Win, N. Kapol, S. Benjawan, and Y. Teerawattananon, “Cost-Utility Analysis of Universal Maternal Pertussis Immunisation in Thailand: A Comparison of Two Model Structures,” Pharmacoeconomics, vol. 41, no. 1, pp. 77–91, Jan. 2023, doi: 10.1007/s40273-022-01207-w.

A. Srisubat et al., “Cost-Utility Analysis of Deep Learning and Trained Human Graders for Diabetic Retinopathy Screening in a Nationwide Program,” Ophthalmol. Ther., vol. 12, no. 2, pp. 1339–1357, Apr. 2023, doi: 10.1007/s40123-023-00688-y.

L. Rodríguez-Campos et al., “Cost–utility analysis of a palliative care program in Colombia,” BMC Palliat. Care, vol. 23, no. 1, Dec. 2024, doi: 10.1186/s12904-024-01476-6.

O. T. Due et al., “Cost-Utility Analysis of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Genotype 1 and 6 in Vietnam,” Value in Health, vol. 23, no. 9, pp. 1180–1190, Sep. 2020, doi: 10.1016/j.jval.2020.03.018.

N. Chitpim, P. Leelahavarong, J. Prawjaeng, S. Ittiphisit, V. Srinonprasert, and T. Kongmalai, “A cost-utility analysis of adding SGLT2 inhibitors for the management of type 2 diabetes with chronic kidney disease in Thailand,” Sci. Rep., vol. 15, no. 1, Dec. 2025, doi: 10.1038/s41598-024-81747-7.

D. Hu et al., “Cost-utility analysis of PCSK9 inhibitors for hypercholesterolemia: a Chinese healthcare perspective,” Front. Pharmacol., vol. 16, 2025, doi: 10.3389/fphar.2025.1708701.

C.-S. Chan et al., “Cost-utility analysis of eptinezumab for migraine prevention in Taiwan,” Health Econ. Rev., Dec. 2025, doi: 10.1186/s13561-025-00711-x.

C. H. Kim et al., “Cost-utility analysis of endoscopic lumbar discectomy following a uniform clinical pathway in the Korean national health insurance system,” PLoS One, vol. 18, no. 6 June, Jun. 2023, doi: 10.1371/journal.pone.0287092.

T. Sawada et al., “Cost-utility analysis of proton beam therapy for locally advanced esophageal cancer in Japan,” PLoS One, vol. 19, no. 9 September, Sep. 2024, doi: 10.1371/journal.pone.0308961.

L. Chen, L. Fang, Z. Kuang, J. Xu, and C. Wang, “Cost utility analysis of adult patients with severe aplastic anemia: a single-center study,” Hematology (United Kingdom), vol. 30, no. 1, 2025, doi: 10.1080/16078454.2025.2492925.

Y. Huang, H. Yuan, and Z. Huang, “Cost-utility analysis of omalizumab for the treatment of chronic spontaneous urticaria in China,” Cost Effectiveness and Resource Allocation, vol. 23, no. 1, Dec. 2025, doi: 10.1186/s12962-025-00643-7.

A. Belančić, I. Stević, E. M. M. Gkrinia, D. Vitezić, and S. Janković, “Cost-utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model,” Br. J. Clin. Pharmacol., 2025, doi: 10.1002/bcp.70379.

Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015;93(2):118–124.

Woods B, Revill P, Sculpher M, Claxton K. Country-level cost-effectiveness thresholds: initial estimates and the need for further research. Value Health. 2016;19(8):929–935.

Most read articles by the same author(s)

1 2 3 4 > >>